Media Summary: Rare Disease Day: A Look at 40 Years of the ... Alexion, AstraZeneca Rare Disease) Rare Disease Day: A Look at 40 Years of the ... Foundation as she talked about the advances made in the rare disease community since the passing of the

Orphan Drug Act 30th Anniversary - Detailed Analysis & Overview

Rare Disease Day: A Look at 40 Years of the ... Alexion, AstraZeneca Rare Disease) Rare Disease Day: A Look at 40 Years of the ... Foundation as she talked about the advances made in the rare disease community since the passing of the ... awards to heroes of the rare disease community at the Watch the presentation to hear us discuss the importance of the Paul Melmeyer, Director of Federal Policy, National Organization for Rare Disorders Cartier Esham, Executive Vice President for ...

Last week, we argued that the benefits of the Emil Kakkis, MD, President and Founder of Ultragenyx Pharmaceutical Inc., explains that while the Welcoming Remarks and Panel 1 (Contextual Considerations and Ethical Issues) Are you developing medicines for rare diseases? If so, our new video from a recent webinar can give you advice on how to devise ... Rare Disease Legislation: A Historical Primer Panel 4 (Price, Cost-Effectiveness, and Affordability) and Adjournment Please note the following correction at 32:15: Patrick ...

Photo Gallery

Orphan Drug Act 30th anniversary
NORD: 30 Years of Advocacy for the Rare Disease Community
Rare Disease Day:  A Look at 40 Years of the Orphan Drug Act
41NBC/WMGT - Orphan Drug Act: Jameson's Story - 5.07.13
NORD, the Orphan Drug Act, and role of rare disease patient advocacy - Video abstract 41070
Sponsor Perspective: Alexion Pharmaceuticals | Rare Disease Day: 40 Years of the Orphan Drug Act
The Orphan Drug Act - How Much Has Changed Since 1983?
Meet the Authors: Orphan Drug Development for Rare Diseases
NORD's Next Generation of Rare Disease Advocates: Ian Brown
What Everyone Affected by a Rare Disease Should Know About the Orphan Drug Act
Paul Melmeyer | Drug Regulation & the Orphan Drug Act
The Canadian Orphan Drug Act Explained
View Detailed Profile
Orphan Drug Act 30th anniversary

Orphan Drug Act 30th anniversary

It's been three decades since

NORD: 30 Years of Advocacy for the Rare Disease Community

NORD: 30 Years of Advocacy for the Rare Disease Community

... the

Rare Disease Day:  A Look at 40 Years of the Orphan Drug Act

Rare Disease Day: A Look at 40 Years of the Orphan Drug Act

Rare Disease Day: A Look at 40 Years of the

41NBC/WMGT - Orphan Drug Act: Jameson's Story - 5.07.13

41NBC/WMGT - Orphan Drug Act: Jameson's Story - 5.07.13

It's been three decades since

NORD, the Orphan Drug Act, and role of rare disease patient advocacy - Video abstract 41070

NORD, the Orphan Drug Act, and role of rare disease patient advocacy - Video abstract 41070

Video abstract of review paper "A

Sponsor Perspective: Alexion Pharmaceuticals | Rare Disease Day: 40 Years of the Orphan Drug Act

Sponsor Perspective: Alexion Pharmaceuticals | Rare Disease Day: 40 Years of the Orphan Drug Act

... Alexion, AstraZeneca Rare Disease) Rare Disease Day: A Look at 40 Years of the

The Orphan Drug Act - How Much Has Changed Since 1983?

The Orphan Drug Act - How Much Has Changed Since 1983?

... Foundation as she talked about the advances made in the rare disease community since the passing of the

Meet the Authors: Orphan Drug Development for Rare Diseases

Meet the Authors: Orphan Drug Development for Rare Diseases

The authors of RAPS'

NORD's Next Generation of Rare Disease Advocates: Ian Brown

NORD's Next Generation of Rare Disease Advocates: Ian Brown

... awards to heroes of the rare disease community at the

What Everyone Affected by a Rare Disease Should Know About the Orphan Drug Act

What Everyone Affected by a Rare Disease Should Know About the Orphan Drug Act

Watch the presentation to hear us discuss the importance of the

Paul Melmeyer | Drug Regulation & the Orphan Drug Act

Paul Melmeyer | Drug Regulation & the Orphan Drug Act

Paul Melmeyer, Director of Federal Policy, National Organization for Rare Disorders Cartier Esham, Executive Vice President for ...

The Canadian Orphan Drug Act Explained

The Canadian Orphan Drug Act Explained

Health Canada plans to introduce its

NORD's Next Generation of Rare Disease Advocates: Megan Barron

NORD's Next Generation of Rare Disease Advocates: Megan Barron

... awards to heroes of the rare disease community at the

Orphan Drugs: Costs

Orphan Drugs: Costs

Last week, we argued that the benefits of the

The Orphan Drug Act is Just One Factor in Orphan Drug Development

The Orphan Drug Act is Just One Factor in Orphan Drug Development

Emil Kakkis, MD, President and Founder of Ultragenyx Pharmaceutical Inc., explains that while the

Orphan Drugs part 4: Fixing the System

Orphan Drugs part 4: Fixing the System

Drug companies love the

ICER Orphan Drug Assessment and Pricing Summit - Part 1 of 3

ICER Orphan Drug Assessment and Pricing Summit - Part 1 of 3

Welcoming Remarks and Panel 1 (Contextual Considerations and Ethical Issues)

Orphan Drug Designation Webinar Video

Orphan Drug Designation Webinar Video

Are you developing medicines for rare diseases? If so, our new video from a recent webinar can give you advice on how to devise ...

Paul Melmeyer : Orphan Drug Act

Paul Melmeyer : Orphan Drug Act

Rare Disease Legislation: A Historical Primer |

ICER Orphan Drug Assessment and Pricing Summit - Part 3 of 3

ICER Orphan Drug Assessment and Pricing Summit - Part 3 of 3

Panel 4 (Price, Cost-Effectiveness, and Affordability) and Adjournment Please note the following correction at 32:15: Patrick ...